TechMARK movers: Oxford Bio down after update

Shares in Oxford BioMedica dropped after interim results from a Phase III study of the gene therapy company's cancer vaccine TroVax did not show a 'significant' survival advantage compared to placebo in the total population.'Although I am disappointed that the trial did not meet its primary endpoint, I believe that TroVax is still of potential benefit to patients with cancer and I hope further studies will be initiated with more refined target populations,' said the Principal UK Investigator for the study, Professor Robert Hawkins of the Christie Hospital in Manchester.Education IT specialist RM said trading so far this year has been in line with expectations. As mentioned at the time of its interim results on 11 May, the company expects revenue to grow this year as a result of its participation in numerous Building Schools for the Future (BSF) programmes. Additionally, the company's recently acquired US subsidiary Computrac will make a contribution whole the board is also looking for growth in the company's general resources business. 'We are reaching the end of what has been the busiest ever summer period for the RM Group. Our focus at this time of year is on operational delivery, which I am pleased to report is going well in each of our three divisions,' said Terry Sweeney, chief executive of RN Group.FTSE TechMARK - FallersOxford Biomedica (OXB) 11.50p -6.12%Innovation Group (TIG) 11.50p -4.17%Optos (OPTS) 81.00p -3.57%RM Group (RM.) 157.25p -2.93%Skyepharma (SKP) 94.00p -2.08%Alterian (ALN) 170.00p -1.73%DRS Data (DRS) 15.25p -1.61%Wolfson Microelectronics (WLF) 145.00p -1.53%Trafficmaster (TFC) 37.50p -1.32%Phoenix IT Group (PNX) 221.50p -1.12%FTSE TechMARK - RisersSinclair Pharma (SPH) 44.50p +17.11%Antisoma (ASM) 35.00p +7.69%Vernalis (VER) 101.00p +6.04%Intec Telecom (ITL) 96.50p +1.58%Puricore (PURI) 16.75p +1.52%Anite Group (AIE) 35.75p +1.42%Microgen (MCGN) 76.00p +1.33%ProStrakan (PSK) 122.00p +0.83%KCOM Group (KCOM) 37.00p +0.68%SDL International (SDL) 391.50p +0.38% Oxford Biomedica Rm